Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.60 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.60 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614852 | 0.91 | CYP4F2 (0.63) | CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7829068 | 0.89 | CYP4F2 (0.61) | CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2302173 | 0.84 | CYP4F2 (0.69) | CYP4F2CYP4A11CDYLCYP1A2CYP3A4 | |
| SCHEMBL2435255 | 0.79 | CYP4F2 (0.63) | CYP4F2CYP4A11CDYLCYP1A2CYP3A4 | |
| SCHEMBL9748816 | 0.79 | TDP1 (0.49) | — | |
| SCHEMBL9748786 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL27674003 | 0.78 | CYP4F2 (0.65) | CYP4F2CYP4A11CDYLCYP1A2CYP3A4 | |
| SCHEMBL69660 | 0.78 | CYP4F2 (0.86) | CYP4F2CYP4A11CDYLCYP1A2CYP3A4 | |
| SCHEMBL490361 | 0.77 | CYP4F2 (0.55) | CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18892727 | 0.77 | MTNR1A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0493404-A4 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | — | 1992-08-12 | — | — | EP | claimed |
| EP-0493404-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-08 | — | — | EP | claimed |
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | claimed |
| US-5091379-A | Dermatitis, side effect reduction | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-25 | — | — | US | claimed |
| WO-1991003227-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | claimed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | claimed |
| EP-0493404-A4 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | — | 1992-08-12 | — | — | EP | disclosed |
| EP-0493404-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5091379-A | Dermatitis, side effect reduction | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-25 | — | — | US | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| WO-1991003227-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |